https://scholars.lib.ntu.edu.tw/handle/123456789/517533
標題: | Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review | 作者: | Tsai Y.C. TSEN-FANG TSAI |
關鍵字: | baricitinib; COVID-19; hydroxychloroquine; immunosuppressant; thalidomide; virus | 公開日期: | 2020 | 出版社: | SAGE Publications Ltd | 卷: | 12 | 來源出版物: | Therapeutic Advances in Musculoskeletal Disease | 摘要: | There have been several episodes of viral infection evolving into epidemics in recent decades, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the latest example. Its high infectivity and moderate mortality have resulted in an urgent need to find an effective treatment modality. Although the category of immunosuppressive drugs usually poses a risk of infection due to interference of the immune system, some of them have been found to exert antiviral properties and are already used in daily practice. Recently, hydroxychloroquine and baricitinib have been proposed as potential drugs for SARS-CoV-2. In fact, there are other immunosuppressants known with antiviral activities, including cyclosporine A, hydroxyurea, minocycline, mycophenolic acid, mycophenolate mofetil, leflunomide, tofacitinib, and thalidomide. The inherent antiviral activity could be a treatment choice for patients with coexisting rheumatological disorders and infections. Clinical evidence, their possible mode of actions and spectrum of antiviral activities are included in this review article. Lay summary: Immunosuppressants often raise the concern of infection risks, especially for patients with underlying immune disorders. However, some disease-modifying antirheumatic drugs (DMARDs) with inherent antiviral activity would be a reasonable choice in the situation of concomitant viral infections and flare up of autoimmune diseases. This review covers DMARDs of treatment potential for SARS-CoV-2 in part I, and antiviral mechanisms plus trial evidence for viruses other than SARS-CoV-2 in part II. ? The Author(s), 2020. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090231476&doi=10.1177%2f1759720X20947296&partnerID=40&md5=d3ed35f1782a5d6167d6a6f76a0236c1 https://scholars.lib.ntu.edu.tw/handle/123456789/517533 |
ISSN: | 1759-720X | DOI: | 10.1177/1759720X20947296 | SDG/關鍵字: | azathioprine; azithromycin; baricitinib; chloroquine; cyclophilin A; cyclosporine; disease modifying antirheumatic drug; gamma interferon; hydroxychloroquine; hydroxyurea; immunosuppressive agent; interleukin 10; interleukin 6; interleukin 8; leflunomide; minocycline; mycophenolate mofetil; mycophenolic acid; T lymphocyte receptor; thalidomide; tofacitinib; tumor necrosis factor; adult; adult respiratory distress syndrome; antiemetic activity; antiretroviral therapy; antiviral activity; case report; CC50 (cytotoxic concentration); clinical article; coronavirus disease 2019; cytokine storm; EC50; female; human; Human immunodeficiency virus 1; Human immunodeficiency virus infection; immunosuppressive treatment; middle aged; mortality; oxygen consumption; polymerase chain reaction; priority journal; randomized controlled trial (topic); Review; Severe acute respiratory syndrome coronavirus 2; virus load; virus replication |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。